×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVO – novo nordisk a/s (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
07:26 am
nvo
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop [Yahoo! Finance]
Low
Report
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop [Yahoo! Finance]
11/21
01:34 am
nvo
Useless Europe is sleepwalking into oblivion [Yahoo! Finance]
Low
Report
Useless Europe is sleepwalking into oblivion [Yahoo! Finance]
11/20
05:41 pm
nvo
Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says [Yahoo! Finance]
Low
Report
Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says [Yahoo! Finance]
11/20
09:43 am
nvo
Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says [Business Insider]
Low
Report
Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says [Business Insider]
11/20
06:23 am
nvo
Is Novo Nordisk Stock a Buy Right Now? [Yahoo! Finance]
Low
Report
Is Novo Nordisk Stock a Buy Right Now? [Yahoo! Finance]
11/20
06:19 am
nvo
Weight-loss drug coverage rises among largest US employers, Mercer survey finds [Yahoo! Finance]
Low
Report
Weight-loss drug coverage rises among largest US employers, Mercer survey finds [Yahoo! Finance]
11/19
02:48 pm
nvo
ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 - The Liver Meeting® [Yahoo! Finance]
Low
Report
ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 - The Liver Meeting® [Yahoo! Finance]
11/19
05:04 am
nvo
How RFK Jr's war on obesity in the age of Ozempic could shake up the booming weight-loss industry [Business Insider]
Low
Report
How RFK Jr's war on obesity in the age of Ozempic could shake up the booming weight-loss industry [Business Insider]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
09:24 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 19
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 19
11/18
11:19 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 18
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 18
11/14
06:04 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 13
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 13
11/13
06:03 am
nvo
Form 6-K NOVO NORDISK A S For: Nov 12
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 12
11/8
05:01 pm
nvo
Form 6-K NOVO NORDISK A S For: Nov 08
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 08
11/8
04:55 pm
nvo
Form 6-K NOVO NORDISK A S For: Nov 08
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 08
11/8
04:53 pm
nvo
Form 6-K NOVO NORDISK A S For: Nov 08
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 08
11/8
04:52 pm
nvo
Form 6-K NOVO NORDISK A S For: Nov 08
Low
Report
Form 6-K NOVO NORDISK A S For: Nov 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Form 6-K NOVO NORDISK A S For: Mar 16
6.0%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
3/16 Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. 4.7%
2/5 Q4/2019 12/31/2019 EPS 3.700 ZacksConsensus 0.550 ActVsEst 3.150 - Beat 4.6%
6/8 Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha] 3.8%
11/8 Novo Nordisk: Actual Numbers Not As Good As Headlines But Still Quite Solid [Seeking Alpha] 3.2%
3/27 Form 6-K NOVO NORDISK A S For: Mar 26 3.2%
8/12 Q2/2019 6/30/2019 EPS 4.030 ZacksConsensus 0.610 ActVsEst 3.420 - Beat 3.0%
9/17 With a backup to the backup, insulin makers say they're primed for Brexit [Reuters (UK)] 3.0%
11/1 Form 6-K NOVO NORDISK A S For: Nov 01 2.7%
8/8 Europe stocks climb in early action, led by pharmas [MarketWatch] 2.4%
TOP News Decliners
9/9
Form 6-K NOVO NORDISK A S For: Sep 09
-3.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
11/20 Form 6-K NOVO NORDISK A S For: Nov 20 -2.8%
12/18 Form 6-K NOVO NORDISK A S For: Dec 16 -2.5%
3/9 Form 6-K NOVO NORDISK A S For: Mar 09 -2.4%
4/7 Team Novo Nordisk and Beyond Type 1 Announce New Partnership -2.4%
1/3 Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward [Yahoo! Finance News] -2.2%
4/28 Form 6-K NOVO NORDISK A S For: Apr 27 -2.1%
9/10 Novo Nordisk A/S (NYSE: NVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.1%
3/23 Form 6-K NOVO NORDISK A S For: Mar 23 -1.8%
10/1 Form 6-K NOVO NORDISK A S For: Sep 30 -1.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: